tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLNN Stock Latest News

Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management
RatingsClene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management
14d ago
CLNN
Clene Inc. Reports Continued Financial Losses in Q3 2025
PremiumCompany Announcements
Clene Inc. Reports Continued Financial Losses in Q3 2025
15d ago
CLNN
Clene reports Q3 EPS (85c), consensus (56c)
PremiumThe Fly
Clene reports Q3 EPS (85c), consensus (56c)
16d ago
CLNN
Clene sees cash runway into 2Q26
PremiumThe Fly
Clene sees cash runway into 2Q26
16d ago
CLNN
Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest
PremiumRatings
Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest
18d ago
CLNN
Is CLNN a Buy, Before Earnings?
PremiumPre-EarningsIs CLNN a Buy, Before Earnings?
20d ago
CLNN
Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh
Premium
Ratings
Clene’s CNM-Au8: A Promising Candidate in ALS Treatment with Buy Rating from Justin Walsh
25d ago
CLNN
Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh
Premium
Ratings
Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh
1M ago
CLNN
Clene Enters Equity Distribution Agreement with Canaccord
PremiumCompany Announcements
Clene Enters Equity Distribution Agreement with Canaccord
1M ago
8K
CLNN
Clene’s Promising Clinical Developments and Strategic Advancements Justify Buy Rating
PremiumRatings
Clene’s Promising Clinical Developments and Strategic Advancements Justify Buy Rating
2M ago
CLNN
Buy Rating for Clene Driven by Promising CNM-Au8 Developments and FDA Support
PremiumRatings
Buy Rating for Clene Driven by Promising CNM-Au8 Developments and FDA Support
2M ago
CLNN
Clene’s Promising Therapeutic Developments and Regulatory Progress Drive Buy Rating
PremiumRatings
Clene’s Promising Therapeutic Developments and Regulatory Progress Drive Buy Rating
2M ago
CLNN
Clene Unveils Promising Clinical Data at ECTRIMS 2025
PremiumCompany AnnouncementsClene Unveils Promising Clinical Data at ECTRIMS 2025
2M ago
8K
CLNN
Clene announces presentation of combined REPAIR-MS results
Premium
The Fly
Clene announces presentation of combined REPAIR-MS results
2M ago
CLNN
Clene price target lowered to $31 from $33 at Benchmark
Premium
The Fly
Clene price target lowered to $31 from $33 at Benchmark
3M ago
CLNN
Clene Expands Equity Distribution to Raise Capital
PremiumCompany Announcements
Clene Expands Equity Distribution to Raise Capital
3M ago
8K
CLNN
Clene files to sell 491,496 shares of common stock for holders
PremiumThe Fly
Clene files to sell 491,496 shares of common stock for holders
3M ago
CLNN
Clene’s CNM-Au8 Shows Promise in Parkinson’s Treatment, Justifying Buy Rating
PremiumRatings
Clene’s CNM-Au8 Shows Promise in Parkinson’s Treatment, Justifying Buy Rating
3M ago
CLNN
Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease
PremiumThe Fly
Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease
3M ago
CLNN
Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease
PremiumThe FlyClene presents preclinical data supporting CNM-Au8 for Parkinson’s disease
3M ago
CLNN
Clene price target lowered to $48 from $83 at Canaccord
Premium
The Fly
Clene price target lowered to $48 from $83 at Canaccord
3M ago
CLNN
Clene Inc. Reports Q2 2025 Financial Results
Premium
Company Announcements
Clene Inc. Reports Q2 2025 Financial Results
4M ago
CLNN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >